HCW Biologics (HCWB) Enterprise Value (2021 - 2026)

HCW Biologics (HCWB) has reported Enterprise Value for 6 consecutive years, with $5.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 565.57% year-over-year to $5.9 million; the trailing twelve-month figure through Jun 2026 stood at $5.9 million (up 565.57% YoY), and the FY2025 full-year result was -$1.6 million, down 20.9% from the prior year.
• Enterprise Value advanced to $5.9 million in Q2 2026 per HCWB's latest filing, from -$1.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at $83.4 million in Q1 2025 and bottomed at -$45.0 million in Q2 2022.
• Historically, Enterprise Value has averaged -$4.5 million across 5 years, with a median of -$1.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 1300.98% in 2024, then sank 143.91% in 2025.
• Over 5 years, Enterprise Value stood at -$27.5 million in 2022, then soared by 115.02% to $4.1 million in 2023, then sank by 132.33% to -$1.3 million in 2024, then decreased by 20.9% to -$1.6 million in 2025, then soared by 464.79% to $5.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $5.9 million, -$1.6 million, and $569082.6 for Q2 2026, Q4 2025, and Q3 2025 respectively.